UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/806,906	03/23/2004	Jonathan J. Langberg	PVI-5813CIP1CON2	2408
	7590 04/02/200 FESCIENCES CORPO	EXAMINER		
LEGAL DEPAI		SCHILLINGER, ANN M		
ONE EDWARI IRVINE, CA 92	· -	ART UNIT	PAPER NUMBER	
			3774	
		MAIL DATE	DELIVERY MODE	
		04/02/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Symmothy		Application No.		Applicant(s)					
		10/806,906	į	LANGBERG ET AL.					
Office Action Summary			Examiner		Art Unit				
			ANN SCHIL	LINGER	3774				
Period fo	The MAILING DATE of this commun or Reply	nication appe	ears on the	cover sheet with the d	correspondence a	ddress			
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).									
Status									
1)⊠	Responsive to communication(s) file	ed on <i>29 .lai</i>	nuary 2008						
,		2b)⊠ This a							
3)		<i>,</i> —			osecution as to th	e merits is			
٥,١	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.								
Dispositi	on of Claims		•	,					
		application							
•	Claim(s) <u>1-37</u> is/are pending in the application.								
	4a) Of the above claim(s) is/are withdrawn from consideration.								
	Claim(s) is/are allowed.								
·	Claim(s) <u>1-37</u> is/are rejected.								
•	Claim(s) is/are objected to.								
8)[_]	Claim(s) are subject to restri	ction and/or	election red	quirement.					
Applicati	on Papers								
9)	The specification is objected to by th	ne Examiner							
10)	The drawing(s) filed on is/are	: a) <u></u> acce	pted or b)	objected to by the	Examiner.				
	Applicant may not request that any obje	ection to the d	Irawing(s) be	held in abeyance. See	e 37 CFR 1.85(a).				
	Replacement drawing sheet(s) including	g the correction	on is required	d if the drawing(s) is ob	jected to. See 37 C	FR 1.121(d).			
11)	The oath or declaration is objected t	o by the Exa	aminer. Not	e the attached Office	Action or form P	TO-152.			
Priority ι	ınder 35 U.S.C. § 119								
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 									
2) Notic 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (Ination Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date			4) Interview Summary Paper No(s)/Mail Di 5) Notice of Informal F 6) Other:	ate				

DETAILED ACTION

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-5, 12, 13, 19-23, 30, and 31 are rejected under 35 U.S.C. 102(e) as being anticipated by Wilson et al. (US Pat. No. 6,569,198). Wilson et al. discloses the following: a method of remodeling a mitral valve annulus to reduce mitral valve regurgitation (col. 3, lines 30-45), comprising the steps of: advancing an adjustable prosthesis (12) in a first configuration to a position adjacent the mitral valve annulus; manipulating the prosthesis from the first configuration toward a second configuration that exerts a compressive force against the mitral valve annulus ((col. 5, lines 25-50); monitoring the degree of regurgitation through transesesophageal echo cardiography while manipulating the prosthesis from the first con figuration toward the second configuration; assessing the degree of regurgitation in response to the monitoring step; adjusting the prosthesis to a third configuration in response to the assessing step (col. 6, lines 15-50). This method may be accomplished by accessing the venous system prior to the transluminally advancing step, or the subclavian vein using a catheter (col. 5, line 65 through col. 6, line 15).

Application/Control Number: 10/806,906 Page 3

Art Unit: 3738

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 6-11 and 24-29 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilson et al. in view of Wright (US Pat. No. 5,522,884). Wilson et al. discloses the invention substantially as claimed, but Wilson et al. does not disclose locking the prosthesis in a certain configuration. Wright teaches mitral annuloplasty rings where the rings are held in place by the various means claimed by the Applicant in col. 1, line 40 through col. 3, line 53 for the purpose of affixing the necessary parts of the prosthesis in their appropriate positions. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made, to use the locking means in order to affix the necessary parts of the prosthesis in their appropriate positions.

Claims 14 and 32 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilson et al. in view of Fowler, Jr. et al. (US Pat. No. 5,086,776). Wilson et al. discloses the invention substantially as claimed, but Wilson et al. does not disclose using surface echo cardiography to monitor the patient's hemodynamic function. Fowler, Jr. et al. teaches methods of monitoring heart performance using surface echo cardiography in col. 1, lines 10-25 to utilize its noninvasive properties. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made, to use surface echo cardiography in order to utilize its noninvasive properties.

Claims 15 and 33 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilson et al. in view of Killman (US Pat. No. 5,846,198). Wilson et al. discloses the invention substantially as claimed, but Wilson et al. does not disclose using intracardiac echo cardiography. Killman teaches heart monitoring means including intracardiac echo cardiography in col. 2, line 55 through col. 3, line 2 for the purpose of utilizing the procedure's improved imaging. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made, to use intracardiac echo cardiography in order to improve imaging of the procedure.

Claims 16 and 34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilson et al. in view of Mehta (US Pat. No. 5,476,453). Wilson et al. discloses the invention substantially as claimed, but Wilson et al. does not disclose using fluoroscopy with radiocontrast media. Mehta teaches methods of coronary repair using fluoroscopy with radiocontrast media in col. 1, lines 34-67 for the purpose of utilizing its visual guiding capabilities. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made, to use fluoroscopy with radiocontrast media in order to utilize its visual guiding capabilities.

Claims 17 and 35 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilson et al. in view of McIntyre (US Pat. No. 5,291,895). Wilson et al. discloses the invention substantially as claimed, but Wilson et al. does not disclose using wedge pressure measurements to monitor hemodynamic function. McIntyre teaches methods of evaluating heart mechanical performance using wedge pressure measurements to monitor hemodynamic function in col. 15, line 61 through col. 16, line 15 for the purpose of utilizing its noninvasive properties. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made,

to use wedge pressure measurements to monitor hemodynamic function in order to utilize its noninvasive properties.

Claims 18, 36, and 37 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wilson et al. in view of Kadhiresan (US Pat. No. 5,935,081). Wilson et al. discloses the invention substantially as claimed, but Wilson et al. does not disclose using an ongoing drug therapy. Kadhiresan teaches long-term heart monitoring procedures using an ongoing drug therapy in col. 4, lines 8-46 for the purpose of improving the patients' quality of life. Therefore, it would have been obvious to one of ordinary skill in the art at the time the invention was made, to use an ongoing drug therapy in order to improve the patients' quality of life.

Response to Arguments

Applicant's arguments with respect to claims 1-37 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to ANN SCHILLINGER whose telephone number is (571)272-6652. The examiner can normally be reached on Mon. thru Fri. 9 a.m. to 4 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4754. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/806,906 Page 6

Art Unit: 3738

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ann Schillinger/ Examiner, Art Unit 3774

/Corrine M McDermott/
Supervisory Patent Examiner, Art Unit 3738